Compare Innodata Inc (INOD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Repligen Corporation Common Stock — how do they compare? Innodata Inc trades at $51.81 (market cap $2.01B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 5.5× Innodata Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 20 Days and Repligen Corporation Common Stock for 0 Days on average.
| INOD | RGEN | |
|---|---|---|
Market Cap | $2.01B | $11.14B |
Volume | 722,859 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $121.50 | $194.57 |
52-Week Low | $34.45 | $102.87 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $1.76B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD is trading at $58.38, down 2.55% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 42.71% gross margins and 37.74% ROE, while expanding into motion-capture AI labs and agentic reinforcement learning. Analyst consensus remains positive with 66.7% buy ratings, though valuation metrics appear elevated with a P/E of 45.26.
The outlook balances strong AI services growth against premium valuation concerns. Investment opportunity lies in continued execution on AI data engineering contracts with major tech companies, while risks include customer concentration and competitive pressures in the rapidly evolving AI infrastructure market.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
